These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 21864230)

  • 41. Relative binding affinities of bisphosphonates for human bone and relationship to antiresorptive efficacy.
    Leu CT; Luegmayr E; Freedman LP; Rodan GA; Reszka AA
    Bone; 2006 May; 38(5):628-36. PubMed ID: 16185944
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Recent advances in understanding the mechanism of action of bisphosphonates.
    Coxon FP; Thompson K; Rogers MJ
    Curr Opin Pharmacol; 2006 Jun; 6(3):307-12. PubMed ID: 16650801
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Bisphosphonates: structure-activity relations from a clinical perspective.
    Papapoulos SE
    Medicina (B Aires); 1997; 57 Suppl 1():61-4. PubMed ID: 9567357
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Potentiating the Anticancer Properties of Bisphosphonates by Nanocomplexation with the Cationic Amphipathic Peptide, RALA.
    Massey AS; Pentlavalli S; Cunningham R; McCrudden CM; McErlean EM; Redpath P; Ali AA; Annett S; McBride JW; McCaffrey J; Robson T; Migaud ME; McCarthy HO
    Mol Pharm; 2016 Apr; 13(4):1217-28. PubMed ID: 26954700
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The role of geranylgeranylation in bone resorption and its suppression by bisphosphonates in fetal bone explants in vitro: A clue to the mechanism of action of nitrogen-containing bisphosphonates.
    van beek E; Löwik C; van der Pluijm G; Papapoulos S
    J Bone Miner Res; 1999 May; 14(5):722-9. PubMed ID: 10320520
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The critical role of bisphosphonates to target bone cancer metastasis: an overview.
    Singh T; Kaur V; Kumar M; Kaur P; Murthy RS; Rawal RK
    J Drug Target; 2015 Jan; 23(1):1-15. PubMed ID: 25203856
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Bisphosphonates: new therapeutic agents for the treatment of bone tumors.
    Heymann D; Ory B; Gouin F; Green JR; Rédini F
    Trends Mol Med; 2004 Jul; 10(7):337-43. PubMed ID: 15242682
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Bisphosphonates for breast cancer: questions answered, questions remaining.
    Layman R; Olson K; Van Poznak C
    Hematol Oncol Clin North Am; 2007 Apr; 21(2):341-67. PubMed ID: 17512453
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Mechanisms of action of bisphosphonates.
    Rodan GA
    Annu Rev Pharmacol Toxicol; 1998; 38():375-88. PubMed ID: 9597160
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Molecular mechanisms of action of bisphosphonates: current status.
    Roelofs AJ; Thompson K; Gordon S; Rogers MJ
    Clin Cancer Res; 2006 Oct; 12(20 Pt 2):6222s-6230s. PubMed ID: 17062705
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Correlation between time-dependent inhibition of human farnesyl pyrophosphate synthase and blockade of mevalonate pathway by nitrogen-containing bisphosphonates in cultured cells.
    Räikkönen J; Taskinen M; Dunford JE; Mönkkönen H; Auriola S; Mönkkönen J
    Biochem Biophys Res Commun; 2011 Apr; 407(4):663-7. PubMed ID: 21420384
    [TBL] [Abstract][Full Text] [Related]  

  • 52. In vivo bone augmentation in an osteoporotic environment using bisphosphonate-loaded calcium deficient apatite.
    Verron E; Gauthier O; Janvier P; Pilet P; Lesoeur J; Bujoli B; Guicheux J; Bouler JM
    Biomaterials; 2010 Oct; 31(30):7776-84. PubMed ID: 20643480
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Progress and problems in oral bisphosphonate].
    Takeuchi Y
    Clin Calcium; 2014 Jan; 24(1):27-33. PubMed ID: 24369277
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Highly potent geminal bisphosphonates. From pamidronate disodium (Aredia) to zoledronic acid (Zometa).
    Widler L; Jaeggi KA; Glatt M; Müller K; Bachmann R; Bisping M; Born AR; Cortesi R; Guiglia G; Jeker H; Klein R; Ramseier U; Schmid J; Schreiber G; Seltenmeyer Y; Green JR
    J Med Chem; 2002 Aug; 45(17):3721-38. PubMed ID: 12166945
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Historical perspectives on the clinical development of bisphosphonates in the treatment of bone diseases.
    Francis MD; Valent DJ
    J Musculoskelet Neuronal Interact; 2007; 7(1):2-8. PubMed ID: 17396000
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [New therapy using bisphosphonate for urolithiasis].
    Yasui T; Niimi K; Hirose M
    Clin Calcium; 2011 Oct; 21(10):1511-5. PubMed ID: 21960237
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Experimental basis for the use of bisphosphonates in Paget's disease of bone.
    Fleisch H
    Clin Orthop Relat Res; 1987 Apr; (217):72-8. PubMed ID: 3549097
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Bisphosphonates and their impact on disseminated tumor cells in early stage breast cancer.
    Li J; Rugo HS
    Breast Dis; 2011; 33(2):83-92. PubMed ID: 22142661
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Inhibitory effects of bisphosphonates on bone resorption].
    Shinoda H
    Nihon Yakurigaku Zasshi; 1995 May; 105(5):285-94. PubMed ID: 7628780
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Ibandronate: pharmacology and preclinical studies.
    Russell RG
    Bone; 2006 Apr; 38(4 Suppl 1):S7-12. PubMed ID: 16531132
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.